In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 5, 2008, Pages 1653-1662

  Lawrence, Laura ^a   Danese, Paul ^a   DeVito, Joe ^a   Franceschi, Francois ^a   Sutcliffe, Joyce ^a,b  

^a Rib X Pharmaceuticals Incorporated   (United States)

^b NanoBio Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CHLORAMPHENICOL; DALFOPRISTIN PLUS QUINUPRISTIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G POTASSIUM; RX 01423; RX 01667; TELITHROMYCIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIOSTASIS; BACTERIUM ISOLATE; DRUG POTENCY; ENTEROCOCCUS; HAEMOPHILUS INFLUENZAE TYPE A; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORAXELLA CATARRHALIS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; BACTERIA; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; ENTEROCOCCUS; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; OXAZOLIDINONES; RESPIRATORY SYSTEM; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 42949106448     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01383-07     Document Type: Article

References (61)

1. Anderegg, T. R., H. S. Sader, T. R. Fritsche, J. E. Ross, and R. N. Jones. 2005. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. Int. J. Antimicrob. Agents 26:13-21.
2. Anderson, R. N., and B. L. Smith. 2005. Deaths: leading causes for 2002. Natl. Vital Stat. Rep. 53:1-89.
3. Arias, C. A., M. V. Villegas, J. Reyes, J. Moreno, L. Xiong, M. Vallejo, K. Lolans, A. S. Mankin, E. Castaneda, and J. Quinn. 2006. Linezolid resistance in the absence of 23S rRNA mutations in methicillin-resistant Staphylococcus aureus, abstr. C2-1147, p. 125. Abstr. 46th Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
4. Auckland, C., L. Teare, F. Cooke, M. E. Kaufmann, M. Warner, G. Jones, K. Bamford, H. Ayles, and A. P. Johnson. 2002. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J. Antimicrob. Chemother. 50:743-746.
5. Bayer, A. S., C. Li, and M. Ing. 1998. Efficacy of trovafloxacin, a new quinolone antibiotic, in experimental staphylococcal endocarditis due to oxacillin-resistant strains. Antimicrob. Agents Chemother. 42:1837-1841.
6. Beekmann, S. E., K. P. Heilmann, S. S. Richter, J. Garcia-de-Lomas, and G. V. Doern. 2005. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002-2003. Results of the multinational GRASP Surveillance Program. Int. J. Antimicrob. Agents 25:148-156.
7. Bonora, M. G., M. Solbiati, E. Stepan, A. Zorzi, A. Luzzani, M. R. Catania, and R. Fontana. 2006. Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage. J. Clin. Microbiol. 44:1153-1155.
8. Brown, S. D., and D. J. Farrell. 2004. Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002. J. Antimicrob. Chemother. 54(Suppl. 1):i23-i29.
9. Brown, S. D., D. J. Farrell, and I. Morrissey. 2004. Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US study. J. Clin. Microbiol. 42:4980-4987.
10. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, Approved standard, 7th ed., vol. 26. CLSI, Wayne, PA.
11. Critchley, I. A., M. E. Jones, P. D. Heinze, D. Hubbard, H. D. Engler, A. T. Evangelista, C. Thornsberry, J. A. Karlowsky, and D. F. Sahm. 2002. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin. Microbiol. Infect. 8:214-221.
12. Dobbs, T. E., M. Patel, K. B. Waites, S. A. Moser, A. M. Stamm, and C. J. Hoesley. 2006. Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center. J. Clin. Microbiol. 44:3368-3370.
13. Doern, G. V., K. P. Heilmann, H. K. Huynh, P. R. Rhomberg, S. L. Coffman, and A. B. Brueggemann. 2001. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob. Agents Chemother. 45:1721-1729.
14. Dunbar, L. M., and D. J. Farrell. 2007. Activity of telithromycin and comparators against isolates of Legionella pneumophila collected from patients with community-acquired respiratory tract infections: PROTEKT years 1-5. Clin. Microbiol. Infect. 13:743-746.
15. Farrell, D. J., and S. G. Jenkins. 2004. Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002. J. Antimicrob. Chemother. 54(Suppl. 1):i17-i22.
16. Farrell, D. J., S. G. Jenkins, S. D. Brown, M. Patel, B. S. Lavin, and K. P. Klugman. 2005. Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg. Infect. Dis. 11:851-858.
17. Farrell, D. J., I. Morrissey, S. Bakker, S. Buckridge, and D. Felmingham. 2004. In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations. Antimicrob. Agents Chemother. 48:3169-3171.
18. Fenelon, L. E., G. Mumtaz, and G. L. Ridgway. 1990. The in-vitro antibiotic susceptibility of Chlamydia pneumoniae. J. Antimicrob. Chemother. 26:763-767.
19. Gillet, Y., B. Issartel, P. Vanhems, J. C. Fournet, G. Lina, M. Bes, F. Vandenesch, Y. Piemont, N. Brousse, D. Floret, and J. Etienne. 2002. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 359:753-759.
20. Gonzales, R. D., P. C. Schreckenberger, M. B. Graham, S. Kelkar, K. DenBesten, and J. P. Quinn. 2001. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357:1179.
21. Herrero, I. A., N. C. Issa, and R. Patel. 2002. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N. Engl. J. Med. 346:867-869.
22. Ippolito, J., Z. Kanyo, B. Wimberly, D. Wang, E. Skripkin, J. Devito, B. Freeborn, J. Sutcliffe, E. Duffy, and F. Franceschi. 2005. Structural basis for the binding of Rx-01, a novel oxazolidinone class, to bacterial ribosomes, abstr. F-1254, p. 197. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
23. Johnson, A. P., L. Tysall, M. W. Stockdale, N. Woodford, M. E. Kaufmann, M. Warner, D. M. Livermore, F. Asboth, and F. J. Allerberger. 2002. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur. J. Clin. Microbiol. Infect. Dis. 21:751-754.
24. Jones, M. E., R. S. Blosser-Middleton, C. Thornsberry, J. A. Karlowsky, and D. F. Sahm. 2003. The activity of levofloxacin and other antimicrobials against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999-2002. Diagn. Microbiol. Infect. Dis. 47:579-586.
25. Jones, M. E., D. C. Draghi, C. Thornsberry, J. A. Karlowsky, D. F. Sahm, and R. P. Wenzel. 2004. Emerging resistance among bacterial pathogens in the intensive care unit - a European and North American Surveillance study (2000-2002). Ann. Clin. Microbiol. Antimicrob. 3:14. http://www.ann- clinmicrob.com/content/3/1/14.
26. Jones, R. N., P. Della-Latta, L. V. Lee, and D. J. Biedenbach. 2002. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 42:137-139.
27. Jones, R. N., T. R. Fritsche, H. S. Sader, and J. E. Ross. 2007. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn. Microbiol. Infect. Dis. 59:309-317.
28. Jones, R. N., J. E. Ross, T. R. Fritsche, and H. S. Sader. 2006. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J. Antimicrob. Chemother. 57:279-287.
29. Karlowsky, J. A., M. E. Jones, D. C. Draghi, C. Thornsberry, D. F. Sahm, and G. A. Volturo. 2004. Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002. Ann. Clin. Microbiol. Antimicrob. 3:7.
30. Long, K. S., J. Poehlsgaard, C. Kehrenberg, S. Schwarz, and B. Vester. 2006. The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptograrnin A antibiotics. Antimicrob. Agents Chemother. 50:2500-2505.
31. Luo, X., K. Harrington, H. Jing, E. Burak, and J. Sutcliffe. 2005. In vivo efficacy of designer oxazolidinones in murine infectious models, abstr. F-1260, p. 199. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
32. Marrie, T. J., M. Poulin-Costello, M. D. Beecroft, and Z. Herman-Gnjidic. 2005. Etiology of community-acquired pneumonia treated in an ambulatory setting. Respir. Med. 99:60-65.
33. Marshall, S. H., C. J. Donskey, R. Hutton-Thomas, R. A. Salata, and L. B. Rice. 2002. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob. Agents Chemother. 46:3334-3336.
34. McCormick, A. W., C. G. Whitney, M. M. Farley, R. Lynfield, L. H. Harrison, N. M. Bennett, W. Schaffner, A. Reingold, J. Hadler, P. Cieslak, M. H. Samore, and M. Lipsitch. 2003. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat. Med. 9:424-430.
35. Meka, V. G., S. K. Pillai, G. Sakoulas, C. Wennersten, L. Venkataraman, P. C. DeGirolami, G. M. Eliopoulos, R. C. Moellering, Jr., and H. S. Gold. 2004. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J. Infect. Dis. 190:311-317.
36. Moran, G. J., A. Krishnadasan, R. J. Gorwitz, G. E. Fosheim, L. K. McDougal, R. B. Carey, and D. A. Talan. 2006. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355:666-674.
37. Pfaller, M. A., A. F. Ehrhardt, and R. N. Jones. 2001. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment. Am. J. Med. 111(Suppl. 9A):4S-12S.
38. Prystowsky, J., F. Siddiqui, J. Chosay, D. L. Shinabarger, J. Millichap, L. R. Peterson, and G. A. Noskin. 2001. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 45:2154-2156.
39. Rahim, S., S. K. Pillai, H. S. Gold, L. Venkataraman, K. Inglima, and R. A. Press. 2003. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin. Infect. Dis. 36:E146-E148.
40. Ridgway, G. L., J. M. Owen, and J. D. Oriel. 1976. A method for testing the antibiotic susceptibility of Chlamydia trachomatis in a cell culture system. J. Antimicrob. Chemother. 2:71-76.
41. Sahm, D. F., J. A. Karlowsky, L. J. Kelly, I. A. Critchley, M. E. Jones, C. Thornsberry, Y. Mauriz, and J. Kahn. 2001. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob. Agents Chemother. 45:1037-1042.
42. Sakoulas, G., H. S. Gold, L. Venkataraman, R. C. Moellering, M. J. Ferraro, and G. M. Eliopoulos. 2003. Introduction of erm(C), into a linezolid- and methicillin-resistant Staphylococcus aureus does not restore linezolid susceptibility. J. Antimicrob. Chemother. 51:1039-1041.
43. Seedat, J., G. Zick, I. Klare, C. Konstabel, N. Weiler, and H. Sahly. 2006. Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection. Antimicrob. Agents Chemother. 50:4217-4219.
44. Seenivasan, M. H., V. L. Yu, and R. R. Muder. 2005. Legionnaires' disease in long-term care facilities: overview and proposed solutions. J. Am. Geriatr. Soc. 53:875-880.
45. Seybold, U., E. V. Kourbatova, J. G. Johnson, S. J. Halvosa, Y. F. Wang, M. D. King, S. M. Ray, and H. M. Blumberg. 2006. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin. Infect. Dis. 42:647-656.
46. Shopsin, B., and B. N. Kreiswirth. 2001. Molecular epidemiology of methicillin-resistant Staphylococcus aureus. Emerg. Infect. Dis. 7:323-326.
47. Skripkin, E., T. McConnell, B. King, J. DeVito, F. Franceschi, and J. Sutcliffe. 2005. Designer oxazolidinones bind to the 50S peptidyl-transferase region and can overcome ribosome-based linezolid resistance, abstr. F-1255, p. 197. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
48. Sokol, W. 2001. Epidemiology of sinusitis in the primary care setting: results from the 1999-2000 Respiratory Surveillance Program. Am. J. Med. 111(Suppl. 9A):19S-24S.
49. Stockdale, M. W., L. Tysall, A. P. Johnson, D. M. Livermore, and N. Woodford. 2004. Low in vitro selection frequencies of enterococcal and staphylococcal mutants resistant to the oxazolidinone AZD2563. Int. J. Antimicrob. Agents 23:88-91.
50. Styers, D., D. J. Sheehan, P. Hogan, and D. F. Sahm. 2006. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann. Clin. Microbiol. Antimicrob. 5:2.
51. Tait-Kamradt, A., J. Clancy, M. Cronan, F. Dib-Hajj, L. Wondrack, W. Yuan, and J. Sutcliffe. 1997. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:2251-2255.
52. Tenover, F. C., L. K. McDougal, R. V. Goering, G. Killgore, S. J. Projan, J. B. Patel, and P. M. Dunman. 2006. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J. Clin. Microbiol. 44:108-118.
53. Toh, S. M., L. Xiong, C. A. Arias, M. V. Villegas, K. Lolans, J. Quinn, and A. S. Mankin. 2007. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol. Microbiol. 64:1506-1514.
54. Tsiodras, S., H. S. Gold, G. Sakoulas, G. M. Eliopoulos, C. Wennersten, L. Venkataraman, R. C. Moellering, and M. J. Ferraro. 2001. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358:207-208.
55. Waites, K. B., L. B. Duffy, T. Schmid, D. Crabb, M. S. Pate, and G. H. Cassell. 1991. In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to Sparfloxacin and PD 127391. Antimicrob. Agents Chemother. 35:1181-1185.
56. Wang, D., E. Sherer, and E. Duffy. 2005. A computational suite for the discovery of designer oxazolidinones suitable for intravenous and oral usage, abstr. F-1853, p. 211. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
57. Wisplinghoff, H., T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, and M. B. Edmond. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.
58. Wolter, N., A. M. Smith, D. J. Farrell, W. Schaffner, M. Moore, C. G. Whitney, J. H. Jorgensen, and K. P. Klugman. 2005. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob. Agents Chemother. 49:3554-3557.
59. Wolter, N., A. M. Smith, D. E. Low, and K. P. Klugman. 2007. High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51:1092-1095.
60. Zhou, J., A. Bhattacharjee, S. Chen, Y. Chen, E. Duffy, J. Farmer, J. Goldberg, R. Hanselmann, J. Ippolito, R. Lou, A. Orbin, A. Oyelere, J. Salvino, D. Springer, J. Tran, D. Wang, and Y. Wu. 2005. Design at the atomic level: synthesis of biaryl oxazolidinones as potent orally active antibiotics, abstr. F-1252, p. 197. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
61. Zurenko, G. E., W. M. Todd, B. Hafkin, B. Meyers, C. Kauffman, J. Bock, J. Slightom, and D. Shinabarger. 1999. Development of linezolid-resis-tant Enterococcus faecium in two compassionate use program patients treated with linezolid, abstr. 0848, p. 118. Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.